What is Nanopath?
Nanopath is fundamentally redefining the diagnostic paradigm through its proprietary biosensing technology. By shifting the capability for high-complexity molecular analysis from centralized laboratories to the point-of-care, the firm enables clinicians to obtain actionable health data in minutes rather than days. This technological leap is particularly focused on women's health and underserved populations, addressing systemic inequities in medical access. The company's platform is designed to integrate seamlessly into clinical workflows, providing a scalable solution that enhances diagnostic precision while reducing the time-to-treatment cycle for patients globally.
How much funding has Nanopath raised?
Nanopath has raised a total of $10M across 1 funding round:
Series A
$10M
Series A (2022): $10M with participation from Norwest Venture Partners, Gingerbread Capital, Green D Ventures, and Medtech Convergence Fund
Key Investors in Nanopath
Gingerbread Capital
Gingerbread Capital is dedicated to closing the funding gap for women-led ventures at early and growth stages, as well as supporting emerging funds led by women and diverse teams.
Green D Ventures
Green D Ventures is a network-powered venture capital firm focused on investing in Dartmouth-connected startups for Dartmouth alumni and their community.
Norwest Venture Partners
Norwest Venture Partners is a premier multi-stage investment firm that partners with founders to build market-leading companies across a wide range of sectors, including healthcare and technology.
What's next for Nanopath?
With this major enterprise-level funding, Nanopath is poised to accelerate its product development roadmap and expand its operational footprint. The strategic focus will likely center on scaling its biosensing platform for broader clinical adoption and navigating the regulatory pathways necessary for widespread deployment. As the company transitions from its current growth phase, the emphasis will remain on refining its diagnostic accuracy and establishing partnerships that solidify its market position. Investors are closely watching how this capital will be deployed to disrupt traditional laboratory models and establish a new standard for rapid, accessible healthcare diagnostics.
See full Nanopath company page
